Johnson and Johnson  (JNJ)
Other Ticker:  
Price: $160.0100 $-0.25 -0.156%
Day's High: $160.41 Week Perf: 1.07 %
Day's Low: $ 157.82 30 Day Perf: -1.01 %
Volume (M): 335 52 Wk High: $ 183.35
Volume (M$): $ 53,577 52 Wk Avg: $166.83
Open: $158.50 52 Wk Low: $150.11

 Market Capitalization (Millions $) 416,906
 Shares Outstanding (Millions) 2,606
 Employees 141,700
 Revenues (TTM) (Millions $) 96,263
 Net Income (TTM) (Millions $) 12,724
 Cash Flow (TTM) (Millions $) 12,768
 Capital Exp. (TTM) (Millions $) 4,265

Johnson And Johnson
Johnson & Johnson, employing approximately 110,600 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field. Through over 200 operating companies, it conducts business in virtually all countries of the world. Johnson & Johnsons primary interest, both historically and currently, has been in products related to human health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1887.

Johnson & Johnson is organized on the principle of decentralized management. The Executive Committee of Johnson & Johnson is the principal management group responsible for the operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments. Each subsidiary within the business segments is, with some exceptions, managed by citizens of the country in which it is located.

Johnson & Johnsons worldwide business is divided into three segments:

Consumer, Pharmaceutical and Medical Devices and Diagnostics.


The Consumer segment manufactures and markets a broad range of products used in the baby and child care, skin care, oral and wound care and womens health care fields, as well as nutritional and over-the-counter pharmaceutical products.


The Pharmaceutical segments principal worldwide franchises are in the antifungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic (central nervous system) and urology fields.


The Medical Devices and Diagnostics segment includes a broad range of products used by or under the direction of physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics.

The international business of Johnson & Johnson is conducted by subsidiaries located in 56 countries outside the United States, which are selling products in virtually all countries throughout the world.


In all their product lines, Johnson & Johnson companies compete with companies both large and small, located in the United States and abroad. Competition is strong in all lines without regard to the number and size of the competing companies involved. Competition in research, involving the development of new products and processes and the improvement of existing products and processes, is particularly significant and results from time to time in product and process obsolescence. The development of new and improved products is important to Johnson & Johnsons success in all areas of its business.

   Company Address: One Johnson & Johnson Plaza New Brunswick 8933 NJ
   Company Phone Number: 524-0400   Stock Exchange / Ticker: NYSE JNJ
   JNJ is expected to report next financial results on July 28, 2023. Next quarterly dividend pay out on September 08, 2023.

Customers Net Income grew by JNJ's Customers Net Profit Margin fell to

5.76 %

4.25 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV        0.96% 
ABT   -2.41%    
BMY   -1.31%    
LLY        0.84% 
PFE        1.59% 
CAH        2.58% 
• View Complete Report

Aridis Pharmaceuticals Inc

Redemption of Losses due to Decrease in orders at the ARDS amid the fiscal interval ending March 31 2023

Investors in Aridis Pharmaceuticals Inc. (ARDS) are in for a rough ride as recent financial results suggest that the company is not in a good financial position. In the fiscal timeframe closing March 31, 2023, the company reported a per-share loss of $-0.22 - a stark contrast to positive earnings experienced by other pharmaceutical companies in the same period.
The decrease in turnover resulted in fading revenue, leading to a larger shortfall. ARDS's revenue dropped by a staggering 8.846% to $1.08 million YoY. This decrease in revenue is alarming as it suggests that there are underlying issues that the company is struggling to address. Revenue is the lifeblood of businesses, and the fact that ARDS's revenue has taken such a significant hit speaks volumes about the company's struggles.

Lifecore Biomedical Inc

Lifecore Biomedical Inc released Revenue of $27.6 million, in the December to February 26 2023

The pharmaceutical industry is a vital sector in the global economy. It is responsible for producing lifesaving drugs, vaccines, and other medical products that improve the lives and health of people globally. However, like any other industry, the pharmaceutical industry also faces its own set of challenges. These challenges range from regulatory and compliance issues to stiff competition and changing market dynamics.
Recently, one of the major pharmaceutical companies shared some good news. The company proclaimed record revenues of $27.6 million in the fiscal year ending February 26, 2023. This achievement is commendable, considering the challenges the pharmaceutical industry faces. However, another company in the sector, Lifecore Biomedical Inc, reported a net deficit of $-40.192 million in the same reporting season.

Globestar Therapeutics Corporation

The Major Pharmaceutical Preparations company caused good story for the stock market, exhibiting a relevant gain in Mar 31 2023 report with operating shortfall of $-0.142059 million

The financial results for the Globestar Therapeutics Corporation (GSTC) for the January to March 31, 2023 reporting cycle have been released, and shareholders were not expecting any moderations at the top-line. However, it appears that they are paying a significant amount of attention to the company's operating shortfall, which was reported at $-0.142059 million during the same period. One positive aspect of this result is that it compares favorably to the performance of the second quarter of 2022, where the operating shortfall was significantly higher at $-0.66231 million. This appears to be a significant indicator for the company's course going forward.
For a company like GSTC, which is on an upward trajectory in terms of revenue generation, it becomes increasingly important to run cost-effectively in order to reach the next chapter of its growth. The good news is that there has been some alleviation on the bottom-line, as the diminishing returns have been cut from the same time frame a year prior. The fiscal span ending in the second quarter of 2023 saw a loss of $-0.150 million, which is lower than the loss of $-0.689 million reported in the same period in 2022. This is a major takeaway from the most recent financial results, which indicates that GSTC is moving in the right direction, albeit at a steady pace.

Q Biomed Inc

The company has Turned into Profitability at the Major Pharmaceutical Preparations company in the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.

23andme Holding Co

Redemption of Diminishing Returns at ME amid the fourth quarter of 2023 earnings season

23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.


Johnson And Johnson's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Total Pharmaceutical
 Segment     of total Revenue
Med. Dev. & Diag.
 Segment     of total Revenue
 Segment     of total Revenue
Skin Care
 Segment     of total Revenue
Total Consumer
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Johnson And Johnson does not provide revenue guidance.

Earnings Outlook
Johnson and Johnson issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071